arrow
E

Eckart Laack

Université Claude Bernard Lyon 1
H指数:31
被引数:8,732

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study

在临床实践中使用阿法替尼治疗EGFR突变阳性的老年非小细胞肺癌患者: 非干预性GIDEON研究的子集分析

2023-01-013
PRE
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
2021-07-0129
OAAI
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Selpercatinib治疗RET融合阳性非小细胞肺癌 (SIREN): 通过access计划治疗的患者的回顾性分析

2021-06-1140
OAAI
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

阿法替尼一线治疗EGFR突变非小细胞肺癌的临床实践

2021-05-0611
OAAI
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
2021-02-0936
OAAI
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

卡马替尼在MET外显子14突变或MET扩增的非小细胞肺癌中的应用

2020-09-03635
OAAI
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
LANCET
IF88.5
2019-11-011.4K
PREAI
Clinical and Molecular Heterogeneity of RTE L1 Deficiency (vol 8, pg 449, 2017)

RTE L1缺乏症的临床和分子异质性 (第8卷,449页,2017)

2017-10-020
OAAI
Clinical and Molecular Heterogeneity of RTEL1 Deficiency

RTEL1缺乏症的临床和分子异质性

2017-05-0141
OAAI
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
LANCET
IF88.5
2009-10-01985
PREAI